Alzheimer’s dementia, Lewy body dementia, and frontotemporal dementia (FTD) are amongst some of the most common forms of dementia. Each type is caused by different biological factors and therefore requires a specific treatment which targets these factors. To develop effective treatments, it is important to correctly diagnose each dementia type, at the earliest possible stage.
The bPRIDE project (blood PRotein ldentification to Discriminate dEmentias) aims to generate and validate blood tests for early and specific diagnosis of the major dementia types. To successfully achieve these aims, bPRIDE will analyse more than 1,000 blood proteins in over 1,000 patients, who are at different stages of these different dementias. This will be done using novel, extremely sensitive technologies.
The hope is to empower people with dementia by giving them specific and early/timely diagnoses, and to assign the most suitable novel treatments to the right people, whilst also increasing the potential for the successful development of potential therapies.
Alzheimer Europe is contributing to this project by supporting its dissemination plan and on 19 February, a communications planning meeting was held with project leaders, attended by Alzheimer Europe Project Officer Ana Diaz and Communications Officer Kate Boor Ellis.
You can find out more about the bPRIDE project, here: PROJECT-bPRIDE.pdf (neurodegenerationresearch.eu)
